NAYA Stock Overview
A life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
NAYA Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.81 |
| 52 Week High | US$1.24 |
| 52 Week Low | US$0.71 |
| Beta | 0 |
| 1 Month Change | -0.80% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| NAYA | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -6.5% | 1.0% | -2.1% |
| 1Y | n/a | 8.7% | 21.3% |
Return vs Industry: Insufficient data to determine how NAYA performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how NAYA performed against the US Market.
Price Volatility
| NAYA volatility | |
|---|---|
| NAYA Average Weekly Movement | 13.6% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NAYA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine NAYA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Steve Shum | nayabiosciences.com |
NAYA Biosciences, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. The company operates in two divisions, NAYA Women’s Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as solid and pediatric tumors; and NY-338, a CD38-targeted FLEX-NK bispecific antibody for multiple myeloma and autoimmune diseases.
NAYA Biosciences, Inc. Fundamentals Summary
| NAYA fundamental statistics | |
|---|---|
| Market cap | US$3.64m |
| Earnings (TTM) | -US$14.86m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs NAYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAYA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.86m |
| Earnings | -US$14.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.32 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -88.6% |
How did NAYA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/12 00:25 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NAYA Biosciences, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|